期刊
JOURNAL OF MEDICAL GENETICS
卷 56, 期 8, 页码 513-520出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/jmedgenet-2018-105714
关键词
next generation sequencing; paraganglioma; pheochromocytoma; somatic mutations; mosaicism
资金
- European Union [633983]
- Institut National du Cancer
- Direction Generale de l'Offre de Soins (PRT-K 2014, COMETE-TACTIC) [INCa-DGOS_8663]
- Cancer Research for Personalized Medicine - CARPEM project (Site de Recherche Integre sur le Cancer - SIRIC)
- Ligue Nationale contre le Cancer (Equipe Labellisee)
- Ligue Nationale contre le Cancer
Background Knowing the genetic status of patients affected by paragangliomas and pheochromocytomas (PPGL) is important for the guidance of their management and their relatives. Our objective was to improve the diagnostic performances of PPGL genetic testing by next-generation sequencing (NGS). Methods We developed a custom multigene panel, which includes 17 PPGL genes and is compatible with both germline and tumour DNA screening. The NGS assay was first validated in a retrospective cohort of 201 frozen tumour DNAs and then applied prospectively to 623 DNAs extracted from leucocytes, frozen or paraffin-embedded PPGL tumours. Results In the retrospective cohort, the sensitivity of the NGS assay was evaluated at 100% for point and indels mutations and 86% for large rearrangements. The mutation rate was re-evaluated from 65% (132/202) to 78% (156/201) after NGS analysis. In the prospective cohort, NGS detected not only germline and somatic mutations but also co-occurring variants and mosaicism. A mutation was identified in 74% of patients for whom both germline and tumour DNA were available. Conclusion The analysis of 824 DNAs from patients with PPGL demonstrated that NGS assay significantly improves the performances of PPGL genetic testing compared with conventional methods, increasing the rate of identified mutations and identifying rare genetic mechanisms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据